Broad Institute

FireFly Neuroscience Announces Healthcare Science and AI Industry Leader David DeCaprio to Join Board of Directors

Retrieved on: 
Mercredi, avril 17, 2024
Harvard University, CMS, WAVD, AI, My Little Pony, Broad Institute, Outline, Human genome, Research, History, Patient, DSM-IV codes, Engineering, MIT, Nursing

FAIRFAX, Va. and TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, announces that Healthcare Science and AI Industry leader, David DeCaprio (“DeCaprio”), has entered into an agreement to join the Company’s Board of Directors upon completion of the anticipated merger with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD).

Key Points: 
  • FAIRFAX, Va. and TORONTO, April 17, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, announces that Healthcare Science and AI Industry leader, David DeCaprio (“DeCaprio”), has entered into an agreement to join the Company’s Board of Directors upon completion of the anticipated merger with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD).
  • This appointment is a key step towards Firefly’s anticipated start of trading on the NASDAQ.
  • DeCaprio has significant experience transitioning advanced technology from academic research labs into successful businesses.
  • He is a Co-founder of ClosedLoop.ai, which has been recognized as the #1 AI platform for healthcare from 2022 through 2024.

Nvelop Therapeutics Announces Members of Its Scientific Advisory Board

Retrieved on: 
Jeudi, mai 2, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Harvard University, Danaher Corporation, Novartis, TIL, PACE, Howard Hughes Medical Institute, MIT, Gene therapy, Broad Institute, Gene editing, Duke University, Beam Therapeutics, Microbiology, Faculty, Harvard Medical School, Mammoth Biosciences, Therapy, Thomas Dudley Cabot, Aarhus University, Molecular genetics, Hospital, Arena, Biomedical engineering, RNA, Editas Medicine, Natural science, Bluebird bio, Kite Pharma, Torque, BioMarin Pharmaceutical, Patient, Gene, HSC, Massachusetts General Hospital, Growth, Pharmaceutical industry

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.
  • Keith Joung, M.D., Ph.D. : Dr. Joung is co-founder of Nvelop Therapeutics, and a pioneer in the development of targeted gene and epigenetic editing technologies.
  • He has co-founded multiple additional biotechnology companies, including Beam Therapeutics, Chroma Medicine, Editas Medicine, Pairwise Plants, SeQure Dx and Verve Therapeutics.
  • He is also the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics and Chroma Medicine.

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality

Retrieved on: 
Jeudi, mai 2, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, GV, Harvard University, Cancer, Genetics, Cell, Broad Institute, Survival, GV (company), Drug resistance, Growth, Overload, Oncogene, Patient, Neoplasm, NIBR, Investment, MIT, Pharmaceutical industry

Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.

Key Points: 
  • Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation.
  • “Our activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
  • Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality.
  • Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways.

Suffolk Hires Peter Gasparini as EVP of National Operations and Chris Mills as EVP of Business Development to Drive Operational Excellence and Accelerate Company Expansion

Retrieved on: 
Jeudi, avril 18, 2024
Architecture, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Education, University, Safety, San Francisco International Airport, Computing, EVP, Broad Institute, Capitol Records, Business development, Passive house, Millennium Tower, Transport, Growth, Fort Worth International Airport, Multimedia, Mission control center, Health, Management

Peter Gasparini joins Suffolk as Executive Vice President, National Operations, and Chris Mills as Executive Vice President, Business Development.

Key Points: 
  • Peter Gasparini joins Suffolk as Executive Vice President, National Operations, and Chris Mills as Executive Vice President, Business Development.
  • The strategic hires enhance the executive team with additional expertise and will help ensure that operational excellence and functional expertise are in alignment across all regions and sectors.
  • Mr. Gasparini will be based in Suffolk Headquarters in Boston and will report to Tim Stroud, National President and Chief Operating Officer at Suffolk.
  • Mr. Mills will focus on national business development efforts to expand Suffolk’s footprint and drive strategic growth.

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

Retrieved on: 
Jeudi, avril 18, 2024
Harvard University, University, Genetics, Post-traumatic stress disorder, Meta-analysis, Fear, Broad Institute, Eurosport 1, Neuroscience, Cognition, PTSD, Chairperson, Trauma, Hand, University of California, Genetic variation, Doctor of Philosophy, Research, URL, Life, Axon guidance, Native, Survivor, Therapy, SURFnet, Mental health, Psychiatric Genomics Consortium, DSM-IV codes, Psychiatric Genetics (journal), Nature Genetics, MIT, Genome, Diagnosis, Biology, NIMH, Synapse, Frequency response, Meat

NEW YORK, April 18, 2024 /PRNewswire/ -- The Global PTSD Genetics initiative founded in 2015 by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Research at Broad Institute, and the Psychiatric Genomics Consortium today announces a pivotal milestone in the genetics of post-traumatic stress disorder (PTSD) has been achieved and published in Nature Genetics on April 18,2024.

Key Points: 
  • Convergent multiomic approaches identified 43 potential causal genes, including modulators of neurotransmitters, ion channels, axon guidance, and synapses.
  • Additional top genes influence stress, immune, fear, and threat-related processes, previously hypothesized to underlie PTSD neurobiology.
  • These findings strengthen the understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
  • Posttraumatic stress disorder (PTSD) is characterized by intrusive thoughts, hyperarousal, avoidance, and negative alterations in cognition and mood that can become persistent for some individuals after traumatic event exposure.

Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets

Retrieved on: 
Mercredi, avril 17, 2024
Drug design, Probability, DOI, Broad Institute, Hematology, Health, Doctor of Philosophy, Disease, Human, Partner (business rank), EV, Optimism, Drug development, Drug discovery, Biotechnology, Gene, Pharmaceutical industry

NEW YORK, April 17, 2024 /PRNewswire/ -- Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced a new study that shows incorporating genetic evidence into drug design significantly increases the probability of successful development by up to 2.6 times compared to when genetic evidence is absent. The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature.¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.

Key Points: 
  • The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature .¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.
  • "These findings further demonstrate that genetic evidence is the most effective means to improve drug discovery and development success rates and R&D efficiency," said Matt Nelson, PhD, Chief Executive Officer of Genscience and Vice President of Genetics and Genomics, Deerfield Discovery and Development (3DC).
  • "This new data helps illustrate the power of genetic evidence to enrich our understanding of the relationship between a potential drug target and the disease we seek to treat."
  • Increasing emphasis on drug mechanisms with supporting genetic evidence is expected to increase success rates and lower the cost of drug discovery and development.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Mardi, avril 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

Curio Bioscience Announces Early Access to the World’s First Product to Transform Single-Cell Sequencing Data into Spatial Context

Retrieved on: 
Mardi, mars 12, 2024
Technology, Research, Nanotechnology, Health Technology, Stem Cells, Biotechnology, Health, General Health, Science, Psychiatry, Broad Institute, B cell, Cell, Massachusetts General Hospital, MIT, Harvard University, Neuroscience, University, Doctor of Philosophy, MD, Trekker, Curio, Hospital, Regeneration, Medical imaging

The first stage of Curio’s commercialization of this new product, called Curio Trekker, is an early access program that already includes world-class research organizations as participants.

Key Points: 
  • The first stage of Curio’s commercialization of this new product, called Curio Trekker, is an early access program that already includes world-class research organizations as participants.
  • “Curio Trekker is the world’s first product that converts single-cell genomics data into single-cell spatial data, enabling a new era of scientific discovery that is simply not possible with today’s standard single-cell sequencing workflows,” said Christina Fan, PhD, Co-founder and CTO of Curio Bioscience.
  • Curio Bioscience has signed a licensing agreement with the Broad Institute, Inc. and is commercializing the technology.
  • “Curio Trekker is the culmination of this work and provides the spatial context that single-cell researchers are lacking today in a readily accessible format.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Mardi, avril 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

Microsoft and NVIDIA announce major integrations to accelerate generative AI for enterprises everywhere

Retrieved on: 
Lundi, mars 18, 2024
Cloud, Microsoft, Sanofi, Microsoft Azure, GTC, Organization, Natural language processing, GPU, Triton, Broad Institute, Public health, Biotechnology, Mass General Brigham, MIT, InfiniBand, Harvard University, SAN, MIG, 3D, Microsoft Power BI, AI, University, First officer (aviation), Software, GENETICS, AUC, VM, LLM, Cloud computing, VMS, Creativity, NIM, Flywheel, NVIDIA, Health, Mass, Silicon, Video game

New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI

Key Points: 
  • New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI
    REDMOND, Wash. and SAN JOSE, Calif., March 18, 2024 /PRNewswire/ -- At GTC on Monday, Microsoft Corp. and NVIDIA expanded their longstanding collaboration with powerful new integrations that leverage the latest NVIDIA generative AI and Omniverse™ technologies across Microsoft Azure, Azure AI services, Microsoft Fabric and Microsoft 365.
  • "AI is transforming our daily lives — opening up a world of new opportunities," said Jensen Huang, founder and CEO of NVIDIA.
  • At NVIDIA GTC , Microsoft is demonstrating a preview of what is possible using Omniverse Cloud APIs on Microsoft Azure.
  • NVIDIA GPUs and NVIDIA Triton Inference Server™ help serve AI inference predictions in Microsoft Copilot for Microsoft 365.